Lutetium (177Lu) vipivotide tetraxetan

DRUG3 trials

Sponsors

Maria Sklodowska-Curie National Research Institute of Oncology, Novartis Pharmaceuticals

Conditions

Adenoid Cystic CarcinomaMetastatic Castration Resistant Prostate CancerProstate Cancer

Phase 2

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial

WithdrawnNCT06199453

Maria Sklodowska-Curie National Research Institute of OncologyAdenoid Cystic Carcinoma

Start: 2024-01-31End: 2027-11-30Updated: 2025-02-10

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

RecruitingNCT06449781

Maria Sklodowska-Curie National Research Institute of OncologyProstate Cancer

Start: 2025-01-09End: 2030-11-30Target: 200Updated: 2025-02-10

Unknown Phase

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

RecruitingNCT06517719

Novartis PharmaceuticalsMetastatic Castration Resistant Prostate Cancer

Start: 2024-09-04End: 2028-02-01Target: 500Updated: 2026-07-13